A. Shen

Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression

P. Zinzani, D. Buglio, J. Zhang, 2014, Blood Cancer Journal.

A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors.

G. Schwartz, L. Pace, M. Gordon, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Differential gene expression in central nervous system lymphoma.

T. Batchelor, M. Shuman, Cigall Kadoch, 2009, Blood.

Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment.

K. Aldape, M. Shuman, L. Damon, 2003, Blood.

Gene expression and angiotropism in primary CNS lymphoma.

J. Fridlyand, K. Aldape, M. Prados, 2006, Blood.

Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma.

J. Fridlyand, M. Prados, J. O'Brien, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

S899 INHIBITION OF C3 WITH APL-2 CONTROLS HAEMOLYSIS AND INCREASES HAEMOGLOBIN LEVELS IN SUBJECTS WITH AUTOIMMUNE HAEMOLYTIC ANAEMIA (AIHA)

M. Gertz, E. Roman, B. Fattizzo, 2019, HemaSphere.

Additive effect of the combination of 5-aza-2’-deoxycytidine and valproic acid in leukemia cell systems

Ajay N. Jain, J. Fridlyand, K. Aldape, 2004 .

Biomarker analysis of pivotal phase II study of oral panobinostat (PAN) in relapsed/refractory Hodgkin lymphoma (HL) patients following autologous stem cell transplant (ASCT).

A. Younes, R. Bugarini, D. Ritchie, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.